Xyrem - Jazz Pharmaceuticals

Cost: $143,604 per U.S. patient per year

Xyrem isn't just plain important for Jazz Pharmaceuticals ($JAZZ). It generates more than half the company's revenue, so it's really, really important. And to keep that revenue coming, Jazz has been raising Xyrem's price--over and over.

According to Bloomberg data, this year Xyrem costs $19.40 per 1-milliliter dose, up from just $2.04 in 2007--an 841% jump. And it's those price hikes that accounted for most of last year's sales growth, according to the Irish company's annual report. Volume increased by 12% last year, with the price rocking up by nearly one-third.

In turn, Jazz boasts a pretty attractive annual profit margin of 54.4%, Investor's Business Daily reported in August. That's one of the best margins out there, the publication said--and not just among pharma companies.

Plenty of other drugmakers have taken note. Jazz routinely makes the list of pharma's top takeover targets, and its Irish address hasn't hurt, either. Whether new U.S. rules on tax inversions change that remains to be seen.

For more:
Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion
Who will be first of 2014 to be bought? Some say Jazz
Jazz strikes up a $120M Concert Pharma collaboration on next-gen Xyrem

-- Carly Helfand (email | Twitter)

Xyrem - Jazz Pharmaceuticals
Read more on

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.